Genotyping Assay Market Size, Share, Trends and Forecast 2026 to 2035

Genotyping Assay Market Size

Genotyping Assay Market is valued at US$ 17.16 billion in 2025 and is projected to reach US$ 46.99 billion by 2035, growing at a CAGR of 10.60% during 2026–2035.

Genotyping assays are becoming a core decision tool for laboratories, biopharmaceutical companies, agriculture researchers, and clinical research organizations that need to identify genetic variation at scale. 

Genotyping assays help identify single nucleotide polymorphisms, copy number variations, and larger DNA structural changes. Their commercial value comes from enabling disease risk assessment, biomarker discovery, drug response prediction, targeted therapy selection, crop improvement, ancestry testing, and large-scale research. For business buyers, the market is increasingly defined by throughput, accuracy, cost per sample, data analysis efficiency, workflow automation, and regulatory confidence.

Key Takeaways

• The Genotyping Assay market size 2026 is recalculated at USD 18.98 billion, showing a large near-term opportunity for assay kit suppliers, sequencing platform companies, and diagnostic workflow providers.
• The market is projected to reach USD 46.99 billion by 2035, supported by a 10.6% CAGR and expanding use across healthcare, agriculture, biotechnology, and research.
• North America holds the largest market share due to strong technology adoption, government support, research funding, and presence of major genomics companies.
• Asia-Pacific is the fastest-growing region as clinical genomics, agricultural biotechnology, and molecular research infrastructure expand across regional markets.
• PCR is expected to dominate by technology because it is widely used, scalable, and suitable for high-throughput genotyping with rapid and accurate results.
• Pricing remains a major adoption issue, particularly for whole-genome resequencing based genotyping, where the source cites approximately USD 400 per sample for a 1 Gb genome at 10 average sequencing depth.
• Genotyping Assay top companies include Thermo Fisher Scientific, Illumina, QIAGEN, Agilent Technologies, LGC, Biosearch Technologies, Roche Diagnostics, Fluidigm Corporation, PerkinElmer, Bio-Rad Laboratories, and Integrated DNA Technologies.

Market Scope

Demand Drivers, Buyer Pain Points, and Market Constraints

Precision Medicine Is Raising the Strategic Value of Genotyping

Precision medicine is one of the strongest Genotyping Assay growth drivers. Genotyping supports patient stratification, disease risk assessment, pharmacogenomics, and targeted therapy decisions. In oncology and inherited disease research, identifying genetic variants helps researchers and clinicians better understand disease mechanisms and treatment response.

Biopharmaceutical companies also use genotyping assays in drug discovery, biomarker identification, and clinical research. As drug developers focus on smaller and more genetically defined patient populations, genotyping becomes more important in trial design, companion diagnostic development, and therapy response evaluation.

PCR, Microarrays, and Next-Generation Sequencing Are Expanding Technical Use Cases

High-throughput genotyping technologies, including PCR-based methods, microarrays, and next-generation sequencing, are increasing the scale and accuracy of genetic analysis. Researchers can use genotyping to study single nucleotide polymorphisms and copy number variations across large numbers of markers and probes.

PCR-based genotyping remains highly practical because it is familiar to laboratories, supports rapid analysis, and enables allelic discrimination through molecular probes. Next-generation sequencing expands discovery potential, while microarrays remain relevant where high-volume, marker-based analysis is required.

Cost Per Sample and Error Risk Remain Key Adoption Barriers

Pricing and adoption trends are shaped by cost, accuracy, workflow burden, and data quality. Whole-genome resequencing based genotyping can be costly, especially in genome-wide association studies involving hundreds of individuals. The source cites approximately USD 400 per sample for a 1 Gb genome using paired-end Illumina technology at 10 average sequencing depth, making budget planning a serious issue for large-scale research programs.

Genotyping errors also affect adoption. Errors may arise from DNA sample quality, biochemical artifacts, primary DNA sequence complexity, low sample quantity, or human factors. For buyers, errors can compromise biological conclusions, reduce confidence in results, and increase repeat testing costs.

Regulatory and Quality Drivers Are Strengthening Clinical Adoption

Supportive regulatory frameworks are helping broader adoption of genotyping assays, particularly in clinical diagnostics and research settings. However, clinical users require strong assay validation, reproducibility, data traceability, and reliable interpretation. Regulatory alignment is especially important when genotyping results influence therapeutic decisions, disease risk communication, or pharmacogenomic recommendations.

Suppliers that provide validated assay kits, compatible software, quality documentation, and standardized workflows are better positioned with hospital laboratories and regulated clinical research buyers.

Practical Use Cases Creating B2B Demand

Genotyping assays are used in oncology research to identify mutations and support targeted therapy development. In pharmacogenomics, they help predict drug response and support personalized treatment selection. In infectious disease research, genotyping enables pathogen variant analysis and epidemiological tracking. In agriculture, assays support crop improvement, trait selection, and genetic diversity studies. In population genomics, genotyping helps analyze genetic variation across large cohorts.

For business buyers, the use case usually determines the technology choice. PCR is attractive for targeted, repeatable, and cost-sensitive applications. Microarrays suit high-volume marker screening. Next-generation sequencing is valuable when broader variant discovery and deeper genomic insight are required.

Substitute Analysis: Where Genotyping Assays Fit

Genotyping assays compete with broader sequencing approaches and narrower molecular tests. Single-marker PCR tests may be sufficient when a specific variant is already known. Whole-genome sequencing provides broader discovery but can be more expensive and data-intensive. Microarrays offer scale for known markers, while next-generation sequencing can support more comprehensive analysis.

Genotyping assays remain commercially attractive because they offer a practical middle ground. They provide targeted genetic insight with better scalability than full genome sequencing and broader utility than single-marker testing.

Genotyping Assay Market Segmentation Analysis

Segmented by Product, by Technology, by End-User, and by Region - Share, Trends, and Forecast to 2035.

By Technology: PCR Holds a Strong Position

The PCR segment is expected to dominate the market during the forecast period. PCR genotyping uses polymerase chain reaction to amplify DNA or RNA sequences with specific primers, followed by analysis for size, quality, and allele discrimination. Real-time PCR is widely used for high-throughput genotyping because it uses molecular probes to generate fast and accurate results.

High-Resolution Melt analysis is another post-PCR approach used in genotyping. PCR’s market strength comes from installed laboratory familiarity, speed, cost efficiency, and compatibility with targeted testing needs.

By Product: Assay Kits, Reagents, Instruments, and Software Support Integrated Workflows

Product demand is tied to laboratory workflow. Assay kits and reagents support repeatable testing, instruments enable scalable analysis, and software supports data interpretation. As laboratories increase sample volumes, buyers are more likely to favor bundled offerings that combine assay chemistry, automation, data analysis, and reporting.

By End-User: Clinical, Research, Biopharma, and Agriculture Buyers Have Distinct Needs

Clinical laboratories prioritize accuracy, turnaround time, regulatory confidence, and reportable results. Research institutes focus on scalability, variant coverage, and data quality. Biopharmaceutical companies use genotyping assays for biomarker discovery, trial stratification, and pharmacogenomics. Agriculture and biotechnology users focus on trait analysis, crop improvement, and genetic mapping.

Genotyping Assay Regional Analysis

North America: Largest Market Share Led by Technology Depth and Research Funding

North America holds the largest share of the global genotyping assay market. Growth is supported by government support, research and development funding, strong clinical genomics adoption, and the presence of major market players. The United States has a strong supplier base, including Thermo Fisher Scientific, which manufactures and distributes scientific instruments, reagents, consumables, and software services.

North American buyers are likely to prioritize high-throughput workflows, validated assay chemistry, laboratory automation, and integrated software. Demand is especially strong in precision medicine, oncology research, pharmacogenomics, and biopharmaceutical development.

Europe: Quality, Clinical Evidence, and Research Collaboration Drive Demand

Europe’s genotyping assay adoption is supported by advanced research institutions, clinical diagnostics demand, and growing use of genomic tools in healthcare and life sciences. The region is likely to emphasize quality control, regulatory compliance, and data reliability, especially where assays are used in clinical decision-making.

European laboratories and research organizations are expected to favor platforms that can support reproducible testing, strong documentation, and compatibility with established laboratory systems.

Asia-Pacific: Fastest Growth From Genomics Infrastructure and Applied Research

Asia-Pacific is the fastest-growing region in the genotyping assay market. Growth is supported by expanding genomics research, rising biotechnology investment, increasing clinical diagnostics adoption, and wider use of genotyping in agriculture and disease research.

The region’s opportunity is broad because demand comes from both healthcare and non-healthcare applications. Agriculture, infectious disease studies, population genomics, and biopharmaceutical research are likely to support long-term adoption.

Competitive Landscape and Company Product Mapping

The global genotyping assay market is moderately competitive, with companies using product launches, acquisitions, workflow innovation, and platform expansion to strengthen their positions. Key players include Thermo Fisher Scientific, Illumina, QIAGEN, Agilent Technologies, LGC, Biosearch Technologies, Roche Diagnostics, Fluidigm Corporation, PerkinElmer, Bio-Rad Laboratories, and Integrated DNA Technologies.

Thermo Fisher Scientific is strongly positioned in PCR-based genotyping through products such as TaqMan SNP Genotyping Assays. These assays use TaqMan 5 nuclease chemistry to amplify and detect specific polymorphisms in purified genomic DNA samples, using sequence-specific primers and probes to genotype single nucleotide polymorphisms.

Illumina is positioned around next-generation sequencing systems and integrated platforms for analyzing genetic variation and biological function. Its iSeq 100 System supports small whole-genome sequencing, targeted sequencing, gene expression analysis, and 16S metagenomics, making it relevant for laboratories seeking accessible sequencing capability.

QIAGEN, Roche Diagnostics, Bio-Rad Laboratories, Agilent Technologies, and Integrated DNA Technologies support the market through assay technologies, reagents, molecular testing tools, and workflow solutions. LGC and Biosearch Technologies add capabilities in assay development and molecular biology tools, while Fluidigm and PerkinElmer support specialized genomic workflows and laboratory technologies.

Recent Developments

• June 2026 – Thermo Fisher Scientific showcases expanded genomics and AI-enabled research capabilities
  Thermo Fisher Scientific introduced new capabilities supporting genomics research, clinical development, and AI-enabled laboratory workflows at BIO International 2026, strengthening its portfolio for precision medicine, molecular diagnostics, and genotyping applications.
• June 2026 – Illumina launches StrataMap Spatial Solution for advanced genomic research
  Illumina introduced the StrataMap Spatial Solution, an end-to-end spatial whole transcriptome research platform that expands genomic analysis capabilities and complements high-throughput sequencing and genotyping workflows used in translational and precision medicine research.
• June 2026 – Agilent Technologies expands AI-driven laboratory innovation
  Agilent collaborated with OpenAI and Boston Consulting Group to accelerate AI-enabled scientific workflows, enhancing laboratory productivity, genomics research, and molecular testing through intelligent data analysis and digital laboratory solutions.
• May 2026 – Illumina and SPT Labtech introduce fireflyGO for targeted oncology research
  Illumina partnered with SPT Labtech to launch fireflyGO, enabling faster and simplified targeted oncology research workflows that support high-throughput genomic analysis and precision oncology applications.
• May 2026 – Illumina introduces distributed whole-genome sequencing solution for MRD research
  Illumina launched the industry's first distributed whole-genome sequencing solution designed for highly sensitive measurable residual disease (MRD) research, expanding genomic testing capabilities applicable to precision oncology and biomarker discovery.
• May 2026 – QIAGEN announces automated Sample-to-Insight workflow with AI integration
  QIAGEN unveiled plans for a fully automated Sample-to-Insight workflow integrated with AI-enabled risk stratification technologies, enhancing molecular testing efficiency, laboratory automation, and precision diagnostic capabilities that complement genotyping assay workflows.
• April 2026 – Thermo Fisher Scientific launches Applied Biosystems PowerFlex Thermal Cycler
  Thermo Fisher Scientific introduced the Applied Biosystems PowerFlex Thermal Cycler, providing improved PCR flexibility, scalability, and productivity for molecular biology, genetic analysis, and genotyping laboratories.
• April 2026 – Illumina releases DRAGEN v4.5 with expanded genomic analysis capabilities
  Illumina launched DRAGEN v4.5 software supporting TruPath Genome and new 5-base assays, enabling improved germline, oncology, and multiomics data analysis while strengthening bioinformatics workflows for genomic testing and genotyping applications.

Report Benefits

This report helps assay manufacturers identify technology segments with stronger adoption potential. It supports sequencing platform companies in assessing demand across PCR, microarray, and next-generation sequencing workflows. Diagnostic laboratories can use the analysis to understand pricing pressure, automation needs, and assay selection criteria. Biopharmaceutical companies can assess genotyping applications in drug discovery, pharmacogenomics, and biomarker development. Investors can evaluate market timing, competitive positioning, and application expansion across healthcare, agriculture, and biotechnology.

Target Audience:

• Genotyping assay manufacturers
• Sequencing platform companies
• Diagnostic laboratories
• Biopharmaceutical companies
• Biotechnology firms
• Research institutes
• Agricultural genomics companies
• Clinical Research Organizations (CROs)
• Bioinformatics solution providers
• Investors in genomics and biotechnology sector
• Procurement teams
• Product managers
• Strategy and planning teams